Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tafinlar
Dabrafenib is a kinase inhibitor primarily used in the treatment of melanoma. It specifically targets BRAF, a protein kinase often mutated in certain cancers, including melanoma, thyroid cancer, and non-small cell lung cancer. By inhibiting BRAF, dabrafenib helps to slow or stop the growth and spread of cancer cells. It is typically used in combination with another drug called trametinib, which targets MEK, another protein kinase in the same signaling pathway. This combination therapy is more effective than dabrafenib alone as it helps to prevent the development of resistance to the drug.
For the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, BRAF V600E mutation-positive anaplastic thyroid cancer, and BRAF V600E mutation-positive non-small cell lung cancer.
Severe cutaneous adverse reactions, new primary malignancies including cutaneous squamous cell carcinoma and keratoacanthoma have been reported with BRAF inhibitors. Secondary malignancies including cutaneous squamous cell carcinoma (cuSCC) can occur. Monitor patients regularly during and after treatment.
Outcome:
Increased dabrafenib levels
Mechanism:
Inhibition of dabrafenib metabolism
Outcome:
Decreased dabrafenib absorption
Mechanism:
Altered gastric pH
Outcome:
Slight increase in dabrafenib absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Extended-release formulation for improved patient compliance (Year: 2026, 75% confidence)
Based on current clinical trial data and market trends, there is a 90% likelihood of continued approval for dabrafenib in combination therapy for advanced melanoma.
Kinase Inhibitor, Antineoplastic
Triazole